Skip to content

Clinical study on treatment of nonalcoholic fatty liver with point application of reducing weight and sticking lipids

Clinical study on treatment of nonalcoholic fatty liver with point application of reducing weight and sticking lipids

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016476
Enrollment
Unknown
Registered
2018-06-03
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver

Interventions

First observation group:(1) the acupoint application of the weight reducing and lowering blood fat patch on the compound acupoint
(2) Control of diet and exercise.
Second observation group:(1) apply the stickers on the single acupoint
Third observation group:(1) the single acupoint application of Chinese medicine is attached to a single point
control group:Diet and exercise control.

Sponsors

Infectious Disease Hospital of Shanghai Pudong District of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) NAFLD diagnostic criteria for western medicine and TCM syndrome differentiation criteria. (2) voluntary participation in this study and the consent of the therapist; (3) male or female patients aged 18-65 years old; (4) no other drugs for the treatment of NAFLD were used in January. Outpatients or inpatients who meet the above criteria can be included in clinical trials.

Exclusion criteria

Exclusion criteria: (1) patients with various viral hepatitis and fatty liver; (2) patients with fatty liver caused by various drugs, poisons, malnutrition, intestinal short circuiting surgery and weight loss in a short time; (3) patients with alcoholic liver disease, viral hepatitis, hepatolenticular degeneration, diabetes, autoimmune liver disease, coronary heart disease, hypertension, stroke, infectious diseases and renal insufficiency; (4) patients with cardiovascular, renal, hepatic abnormalities, mental disorders and severe allergic constitution are not suitable for acupoint application therapy.

Design outcomes

Primary

MeasureTime frame
CAP value of instantaneous elastic scanner;liver function;

Secondary

MeasureTime frame
blood fat;BMI;Symptoms of Chinese Medicine ;

Countries

China

Contacts

Public ContactYang Cheng

Infectious Disease Hospital of Shanghai Pudong District of Shanghai

hk5771@126.com+86 13585980751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026